

Paul Toren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5154108/publications.pdf>

Version: 2024-02-01

51
papers

935
citations

567144

15
h-index

454834

30
g-index

53
all docs

53
docs citations

53
times ranked

1697
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review). <i>International Journal of Oncology</i> , 2014, 45, 1793-1801.	1.4	142
2	Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT. <i>Journal of Clinical Oncology</i> , 2015, 33, 1151-1156.	0.8	139
3	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. <i>European Urology</i> , 2015, 67, 986-990.	0.9	91
4	Results of a National Population-based Study of Outcomes of Surgery for Renal Tumors Associated With Inferior Vena Cava Thrombus. <i>Urology</i> , 2013, 82, 572-578.	0.5	55
5	Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. <i>Prostate</i> , 2019, 79, 1767-1776.	1.2	51
6	Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study. <i>Canadian Urological Association Journal</i> , 2013, 7, 692.	0.3	37
7	Periprostatic Adipose Tissue and Prostate Cancer Progression: New Insights into the Tumor Microenvironment. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 21-26.	0.9	31
8	Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0152861.	1.1	30
9	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 342-349.	0.8	27
10	Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. <i>BMJ, The</i> , 2013, 346, f2109-f2109.	3.0	25
11	PEG10 is associated with treatment-induced neuroendocrine prostate cancer. <i>Journal of Molecular Endocrinology</i> , 2019, 63, 39-49.	1.1	25
12	Sex steroids in the tumor microenvironment and prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2018, 25, R179-R196.	1.6	24
13	Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 300.e9-300.e15.	0.8	21
14	Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy. <i>Canadian Journal of Urology</i> , 2009, 16, 4716-20.	0.0	21
15	Diet, Obesity, and Cancer Progression: Are Adipocytes the Link?. <i>Lipid Insights</i> , 2013, 6, LPI.S10871.	1.0	17
16	Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 363.e7-363.e11.	0.8	16
17	Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies. <i>Canadian Urological Association Journal</i> , 2013, 4, 12.	0.3	15
18	Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. <i>European Urology Oncology</i> , 2020, 3, 298-305.	2.6	15

#	ARTICLE	IF	CITATIONS
19	The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy. Canadian Urological Association Journal, 2013, 3, 465.	0.3	13
20	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. Clinical Cancer Research, 2018, 24, 5305-5312.	3.2	13
21	Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. European Urology Focus, 2021, 7, 1044-1051.	1.6	13
22	Active surveillance in patients with a PSA >10 ng/mL. Canadian Urological Association Journal, 2014, 8, 702.	0.3	12
23	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association Journal, 2020, 14, 319-321.	0.3	11
24	Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5 α -reductase inhibitors. BJU International, 2018, 121, 399-404.	1.3	10
25	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. Clinical Genitourinary Cancer, 2019, 17, e1122-e1128.	0.9	9
26	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World Journal of Urology, 2021, 39, 1549-1558.	1.2	9
27	Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and Translational Medicine, 2022, 12, e581.	1.7	9
28	Extragenital Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. Journal of Urology, 2020, 203, 940-948.	0.2	8
29	Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs. Scientific Reports, 2021, 11, 19299.	1.6	6
30	Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections, 2019, 8, 132-140.	0.8	6
31	Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. Canadian Urological Association Journal, 2019, 14, 36-41.	0.3	5
32	Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer?. Bladder Cancer, 2020, 6, 63-69.	0.2	5
33	Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. Journal of Urology, 2021, 206, 1166-1176.	0.2	5
34	Rational cotargeting of Pim-1 and Akt in prostate cancer. Expert Review of Anticancer Therapy, 2013, 13, 937-939.	1.1	4
35	Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy. Canadian Urological Association Journal, 2013, 4, 133.	0.3	3
36	982 COMBINED TARGETING OF PI3K/AKT AND AR PATHWAY WITH AZD5363 AND ENZALUTAMIDE INDUCES ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF PROSTATE CANCER. Journal of Urology, 2013, 189, .	0.2	2

#	ARTICLE	IF	CITATIONS
37	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian Journal of Andrology, 2022, 24, 21.	0.8	2
38	Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical Nutrition ESPEN, 2022, 47, 221-226.	0.5	2
39	Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 303.e1-303.e8.	0.8	1
40	Analysis of the translome in solid tumors using polyribosome profiling/RNA-Seq. Journal of Biological Methods, 2016, 3, e59.	1.0	1
41	Assembling a network to promote translational bladder cancer research in Canada. Canadian Urological Association Journal, 2020, 14, E475-E481.	0.3	1
42	236 EXPERIENCE WITH RECTOURETHRAL FISTULA REPAIR AND DESCRIPTION OF A NOVEL SURGICAL TECHNIQUE. Journal of Urology, 2012, 187, .	0.2	0
43	PD32-01 PRE-CLINICAL RATIONALE FOR COMBINATION PI3K AND BRD4 INHIBITION IN ADVANCED PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0
44	MP62-06 COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRE-CLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0
45	Images â€œ Para-aortic lymphatic ectasia suggestive of testicular cancer retroperitoneal metastasis. Canadian Urological Association Journal, 2020, 15, E76-E78.	0.3	0
46	Reply by Authors. Journal of Urology, 2021, 206, 1176.	0.2	0
47	The patient presenting with genitourinary AIDS. , 2005, , 263-280.		0
48	Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer.. Journal of Clinical Oncology, 2016, 34, 234-234.	0.8	0
49	Images - Sclerosing mesenteritis presenting with unilateral hydro-ureteronephrosis. Canadian Urological Association Journal, 2019, , E306-E308.	0.3	0
50	Case â€œ Gigantic obstructive calculi in continent urinary diversion. Canadian Urological Association Journal, 2022, 16, .	0.3	0
51	Sex steroid modulation of macrophages within the prostate tumor microenvironment.. American Journal of Clinical and Experimental Urology, 2022, 10, 98-110.	0.4	0